
Commentary|Videos|December 10, 2024
Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL
John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.
Advertisement
John M. Burke, MD, hematologist, medical oncologist, Rocky Mountain Cancer Centers, Sarah Cannon Cancer Institute, discusses results from a United States community-based healthcare practitioner survey, highlighting best practices to overcoming challenges in initiating venetoclax (Venclexta) for patients with chronic lymphocytic leukemia. These findings were presented by Burke at the 2024 ASH Annual Meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5



































